National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2.
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other opioids. Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. Longer duration of treatment allows restoration of social connections and is associated with better outcomes. Treatments for OUD may be limited by poor adherence to treatment recommendations and by high rates of relapse and increased risk of overdose after leaving treatment. Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication. New depot and implant formulations of buprenorphine and naltrexone have been developed to address issues of safety and problems of poor treatment adherence. For people with OUD who do not respond to these treatments, there is accumulating evidence for supervised injectable opioid treatment (prescribing pharmaceutical heroin). Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose. All medication-assisted treatment is limited by lack of access and by stigma. In seeking to stem the rising toll from OUD, expanding access to approved treatment such as methadone, for which there remains the best evidence of efficacy, may be the most useful approach.
阿片类药物使用障碍(OUD)是一种慢性、复发性疾病,常与法律、人际关系和就业问题有关。已证明对 OUD 有效的药物有美沙酮(一种完全阿片激动剂)、丁丙诺啡(一种部分激动剂)和纳曲酮(一种阿片拮抗剂)。美沙酮和丁丙诺啡通过抑制阿片戒断症状和减弱其他阿片类药物的作用来发挥作用。纳曲酮阻断阿片类激动剂的作用。口服美沙酮具有最强的疗效证据。治疗时间越长,越能恢复社会联系,结果越好。OUD 的治疗可能受到以下因素的限制:对治疗建议的依从性差,复发率高,以及离开治疗后过量用药的风险增加。美沙酮和丁丙诺啡治疗还有药物滥用和转移的额外风险。为了解决安全性问题和治疗依从性差的问题,新的丁丙诺啡和纳曲酮储库和植入剂配方已被开发出来。对于对这些治疗方法没有反应的 OUD 患者,越来越多的证据表明监督注射阿片类药物治疗(开处方海洛因)是有效的。另一种最大限度降低用药过量风险的药物模式是携带纳洛酮回家。纳洛酮是一种阿片拮抗剂,用于逆转阿片类药物过量,携带纳洛酮回家计划旨在预防致命的过量用药。所有的药物辅助治疗都受到缺乏获得途径和耻辱感的限制。在寻求遏制 OUD 上升带来的影响时,扩大对美沙酮等经批准的治疗方法的获取可能是最有用的方法,因为美沙酮在疗效方面的证据最好。